Influence of Tacrolimus and Short-Duration Prednisone on Bone Mineral Density Following Liver Transplantation

James S. Scolapio, Jennifer DeArment, Daniel L. Hurley, Michele Romano, Denise Harnois, Stephen D. Weigand

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Osteoporosis is a known complication of chronic prednisone use. Patients with end stage liver disease (ESLD) are prone to develop osteopenia and osteoporosis, and additional bone loss may occur with the use of immunosuppression agents after orthotopic liver transplant (OLT). The aim of this study was to determine the effect of tacrolimus (FK506) and short-duration (4 month) prednisone immunosuppression therapy on bone mineral density (BMD) after OLT of patients with cirrhotic ESLD. Methods: Forty-nine patients with cirrhotic ESLD (26 men, 23 women; median age 54 years) had dual energy x-ray absorptiometry preformed at baseline and 4 and 12 months after OLT. Immunosuppression therapy after OLT included a standard transplant protocol of daily tacrolimus to maintain plasma levels between 0.2 to 0.5 ng/mL and daily oral prednisone tapered over 4 months. BMD was measured at the lumbar spine (L-BMD) and left hip (hip BMD) and reported as raw density (g/cm2) and T score (standard deviations from gender-matched young healthy subjects). Results represent total hip measurements. Two-sided paired t test and analysis of variance methods were used for statistical comparisons. Results: Significant improvement in L-BMD was seen at 4 and 12 months. Hip BMD declined at 4 months but was stable thereafter between 4 and 12 months. BMD results did not differ between gender and liver disease types. Conclusions: Tacrolimus and short-duration prednisone administration after OLT was not associated with bone loss at the lumbar spine at either 4 or 12 months. Significant bone loss occurred at the hip during the 4 months of prednisone administration after OLT but was stable thereafter. These findings suggest that immunosuppression protocols that use lower doses of prednisone administration over shorter time intervals may help prevent bone loss after OLT.

Original languageEnglish (US)
Pages (from-to)427-432
Number of pages6
JournalJournal of Parenteral and Enteral Nutrition
Volume27
Issue number6
StatePublished - Nov 2003

Fingerprint

tacrolimus
prednisone
liver transplant
bone density
Tacrolimus
Prednisone
Liver Transplantation
Bone Density
hips
Transplants
immunosuppression
liver diseases
duration
Liver
Immunosuppression
End Stage Liver Disease
bones
lumbar spine
Pelvic Bones
Hip

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Influence of Tacrolimus and Short-Duration Prednisone on Bone Mineral Density Following Liver Transplantation. / Scolapio, James S.; DeArment, Jennifer; Hurley, Daniel L.; Romano, Michele; Harnois, Denise; Weigand, Stephen D.

In: Journal of Parenteral and Enteral Nutrition, Vol. 27, No. 6, 11.2003, p. 427-432.

Research output: Contribution to journalArticle

Scolapio, James S. ; DeArment, Jennifer ; Hurley, Daniel L. ; Romano, Michele ; Harnois, Denise ; Weigand, Stephen D. / Influence of Tacrolimus and Short-Duration Prednisone on Bone Mineral Density Following Liver Transplantation. In: Journal of Parenteral and Enteral Nutrition. 2003 ; Vol. 27, No. 6. pp. 427-432.
@article{47c94c8cb5d6483fa298b148816e15e2,
title = "Influence of Tacrolimus and Short-Duration Prednisone on Bone Mineral Density Following Liver Transplantation",
abstract = "Background: Osteoporosis is a known complication of chronic prednisone use. Patients with end stage liver disease (ESLD) are prone to develop osteopenia and osteoporosis, and additional bone loss may occur with the use of immunosuppression agents after orthotopic liver transplant (OLT). The aim of this study was to determine the effect of tacrolimus (FK506) and short-duration (4 month) prednisone immunosuppression therapy on bone mineral density (BMD) after OLT of patients with cirrhotic ESLD. Methods: Forty-nine patients with cirrhotic ESLD (26 men, 23 women; median age 54 years) had dual energy x-ray absorptiometry preformed at baseline and 4 and 12 months after OLT. Immunosuppression therapy after OLT included a standard transplant protocol of daily tacrolimus to maintain plasma levels between 0.2 to 0.5 ng/mL and daily oral prednisone tapered over 4 months. BMD was measured at the lumbar spine (L-BMD) and left hip (hip BMD) and reported as raw density (g/cm2) and T score (standard deviations from gender-matched young healthy subjects). Results represent total hip measurements. Two-sided paired t test and analysis of variance methods were used for statistical comparisons. Results: Significant improvement in L-BMD was seen at 4 and 12 months. Hip BMD declined at 4 months but was stable thereafter between 4 and 12 months. BMD results did not differ between gender and liver disease types. Conclusions: Tacrolimus and short-duration prednisone administration after OLT was not associated with bone loss at the lumbar spine at either 4 or 12 months. Significant bone loss occurred at the hip during the 4 months of prednisone administration after OLT but was stable thereafter. These findings suggest that immunosuppression protocols that use lower doses of prednisone administration over shorter time intervals may help prevent bone loss after OLT.",
author = "Scolapio, {James S.} and Jennifer DeArment and Hurley, {Daniel L.} and Michele Romano and Denise Harnois and Weigand, {Stephen D.}",
year = "2003",
month = "11",
language = "English (US)",
volume = "27",
pages = "427--432",
journal = "Journal of Parenteral and Enteral Nutrition",
issn = "0148-6071",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Influence of Tacrolimus and Short-Duration Prednisone on Bone Mineral Density Following Liver Transplantation

AU - Scolapio, James S.

AU - DeArment, Jennifer

AU - Hurley, Daniel L.

AU - Romano, Michele

AU - Harnois, Denise

AU - Weigand, Stephen D.

PY - 2003/11

Y1 - 2003/11

N2 - Background: Osteoporosis is a known complication of chronic prednisone use. Patients with end stage liver disease (ESLD) are prone to develop osteopenia and osteoporosis, and additional bone loss may occur with the use of immunosuppression agents after orthotopic liver transplant (OLT). The aim of this study was to determine the effect of tacrolimus (FK506) and short-duration (4 month) prednisone immunosuppression therapy on bone mineral density (BMD) after OLT of patients with cirrhotic ESLD. Methods: Forty-nine patients with cirrhotic ESLD (26 men, 23 women; median age 54 years) had dual energy x-ray absorptiometry preformed at baseline and 4 and 12 months after OLT. Immunosuppression therapy after OLT included a standard transplant protocol of daily tacrolimus to maintain plasma levels between 0.2 to 0.5 ng/mL and daily oral prednisone tapered over 4 months. BMD was measured at the lumbar spine (L-BMD) and left hip (hip BMD) and reported as raw density (g/cm2) and T score (standard deviations from gender-matched young healthy subjects). Results represent total hip measurements. Two-sided paired t test and analysis of variance methods were used for statistical comparisons. Results: Significant improvement in L-BMD was seen at 4 and 12 months. Hip BMD declined at 4 months but was stable thereafter between 4 and 12 months. BMD results did not differ between gender and liver disease types. Conclusions: Tacrolimus and short-duration prednisone administration after OLT was not associated with bone loss at the lumbar spine at either 4 or 12 months. Significant bone loss occurred at the hip during the 4 months of prednisone administration after OLT but was stable thereafter. These findings suggest that immunosuppression protocols that use lower doses of prednisone administration over shorter time intervals may help prevent bone loss after OLT.

AB - Background: Osteoporosis is a known complication of chronic prednisone use. Patients with end stage liver disease (ESLD) are prone to develop osteopenia and osteoporosis, and additional bone loss may occur with the use of immunosuppression agents after orthotopic liver transplant (OLT). The aim of this study was to determine the effect of tacrolimus (FK506) and short-duration (4 month) prednisone immunosuppression therapy on bone mineral density (BMD) after OLT of patients with cirrhotic ESLD. Methods: Forty-nine patients with cirrhotic ESLD (26 men, 23 women; median age 54 years) had dual energy x-ray absorptiometry preformed at baseline and 4 and 12 months after OLT. Immunosuppression therapy after OLT included a standard transplant protocol of daily tacrolimus to maintain plasma levels between 0.2 to 0.5 ng/mL and daily oral prednisone tapered over 4 months. BMD was measured at the lumbar spine (L-BMD) and left hip (hip BMD) and reported as raw density (g/cm2) and T score (standard deviations from gender-matched young healthy subjects). Results represent total hip measurements. Two-sided paired t test and analysis of variance methods were used for statistical comparisons. Results: Significant improvement in L-BMD was seen at 4 and 12 months. Hip BMD declined at 4 months but was stable thereafter between 4 and 12 months. BMD results did not differ between gender and liver disease types. Conclusions: Tacrolimus and short-duration prednisone administration after OLT was not associated with bone loss at the lumbar spine at either 4 or 12 months. Significant bone loss occurred at the hip during the 4 months of prednisone administration after OLT but was stable thereafter. These findings suggest that immunosuppression protocols that use lower doses of prednisone administration over shorter time intervals may help prevent bone loss after OLT.

UR - http://www.scopus.com/inward/record.url?scp=1642472798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642472798&partnerID=8YFLogxK

M3 - Article

C2 - 14621125

AN - SCOPUS:1642472798

VL - 27

SP - 427

EP - 432

JO - Journal of Parenteral and Enteral Nutrition

JF - Journal of Parenteral and Enteral Nutrition

SN - 0148-6071

IS - 6

ER -